Screener
BridgeBio Pharma BBIO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 5,226 | 5,366 |
| Operating lease right-of-use assets | 17,079 | 8,149 |
| Intangible assets, net | 26,641 | 28,077 |
| Other assets | 20,120 | 16,712 |
| Total assets | $1,217,299 | $936,025 |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $27,202 | $36,228 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's deferred tax assets and other non-current assets?
- BridgeBio Pharma (BBIO) reported deferred tax assets and other non-current assets of $20.12M in Q2 2026.
- How has BridgeBio Pharma's deferred tax assets and other non-current assets changed year-over-year?
- BridgeBio Pharma's deferred tax assets and other non-current assets increased by 11.1% year-over-year, from $18.11M to $20.12M.
- What is the long-term trend for BridgeBio Pharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's deferred tax assets and other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about BridgeBio Pharma's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude